Select Publications
Journal articles
, 2007, 'The Fas/Fas ligand system inhibits differentiation of murine osteoblasts but has a limited role in osteoblast and osteoclast apoptosis', Journal of Immunology, 178, pp. 3379 - 3389, http://dx.doi.org/10.4049/jimmunol.178.6.3379
, 2007, 'A new xenograft model of myeloma bone disease demonstrating the efficacy of human mesenchymal stem cells expressing osteoprotegerin by lentiviral gene transfer', Leukemia, 21, pp. 2181 - 2191, http://dx.doi.org/10.1038/sj.leu.2404814
, 2007, 'Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment', Leukemia, 21, pp. 805 - 812, http://dx.doi.org/10.1038/sj.leu.2404518
, 2007, 'An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma', Cancer Research, 67, pp. 202 - 208, http://dx.doi.org/10.1158/0008-5472.CAN-06-1287
, 2006, 'Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma', British Journal of Haematology, 135, pp. 688 - 692, http://dx.doi.org/10.1111/j.1365-2141.2006.06356.x
, 2006, 'Bortezomib Reduces Serum Dickkopf-1 and RANKL Concentrations and Normalizes Indices of Bone Remodeling in Patients with Relapsed Multiple Myeloma.', Blood, 108, pp. 506 - 506, http://dx.doi.org/10.1182/blood.v108.11.506.506
, 2006, 'Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Inhibit Osteoclast Activation and Increase Trabecular Bone Area in a Xenogeneic Murine Model of Myeloma.', Blood, 108, pp. 505 - 505, http://dx.doi.org/10.1182/blood.v108.11.505.505
, 2006, 'Inhibition of p38α MAPK Reduces Tumor Burden, Prevents the Development of Myeloma Bone Disease, and Increases Survival in the 5T2 and 5T33 Murine Models of Myeloma.', Blood, 108, pp. 3436 - 3436, http://dx.doi.org/10.1182/blood.v108.11.3436.3436
, 2006, 'The Combination of Bortezomib, Melphalan, Dexamethasone and Intermittent Thalidomide (VMDT) Is an Effective Regimen for Relapsed/Refractory Myeloma and Reduces Serum Levels of Dickkopf-1, RANKL, MIP-1α and Angiogenic Cytokines.', Blood, 108, pp. 3541 - 3541, http://dx.doi.org/10.1182/blood.v108.11.3541.3541
, 2006, 'Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: A study in the 5TMM model', Clinical and Experimental Metastasis, 23, pp. 291 - 300, http://dx.doi.org/10.1007/s10585-006-9038-6
, 2006, 'Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation', International Journal of Cancer, 119, pp. 1728 - 1731, http://dx.doi.org/10.1002/ijc.22033
, 2006, 'ADAM-9 (MDC-9/meltrin-γ), a member of the a disintegrin and metalloproteinase family, regulates myeloma-cell-induced interleukin-6 production in osteoblasts by direct interaction with the α
, 2006, '663. Gene Modified Human Mesenchymal Stem Cells Expressing Osteoprotegerin Reverse Osteoclast Activation in a Xenogeneic Murine Model of Multiple Myeloma', Molecular Therapy, 13, pp. S256 - S256, http://dx.doi.org/10.1016/j.ymthe.2006.08.740
, 2005, 'Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo - A role in tumour cell survival?', Breast Cancer Research and Treatment, 92, pp. 207 - 215, http://dx.doi.org/10.1007/s10549-005-2419-8
, 2005, 'The 5T2MM murine model of multiple myeloma: maintenance and analysis.', Methods in molecular medicine, 113, pp. 191 - 205
, 2005, 'Expression of RANKL, OPG, PTHrP and OCIL in multiple myeloma are influenced by the tumor cells` proximity to bone', Journal of Bone and Mineral Research, 20, pp. S211 - S211
, 2004, 'The RANKL system and the development of tumor-induced bone disease: Lessons from pre-clinical models', Journal of Musculoskeletal Neuronal Interactions, 4, pp. 285 - 292
, 2004, 'Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer', Prostate, 59, pp. 304 - 310, http://dx.doi.org/10.1002/pros.20016
, 2004, 'Evidence of a role for RANKL in the development of myeloma bone disease', Current Opinion in Pharmacology, 4, pp. 340 - 346, http://dx.doi.org/10.1016/j.coph.2004.03.011
, 2004, 'Multifunctional role of matrix metalloproteinases in multiple myeloma: A study in the 5T2MM mouse model', American Journal of Pathology, 165, pp. 869 - 878, http://dx.doi.org/10.1016/S0002-9440(10)63349-4
, 2004, 'Myeloma cells (5TMM) and their interactions with the marrow microenvironment', Blood Cells, Molecules, and Diseases, 33, pp. 111 - 119, http://dx.doi.org/10.1016/j.bcmd.2004.04.012
, 2003, 'Multiple myeloma biology: Lessons from the 5TMM models', Immunological Reviews, 194, pp. 196 - 206, http://dx.doi.org/10.1034/j.1600-065X.2003.00035.x
, 2003, 'Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells', Cancer Research, 63, pp. 912 - 916
, 2003, 'Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: Evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival', Journal of Bone and Mineral Research, 18, pp. 482 - 492, http://dx.doi.org/10.1359/jbmr.2003.18.3.482
, 2003, 'Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma', Cancer Research, 63, pp. 287 - 289
, 2003, 'Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin', Immunity, 19, pp. 849 - 861, http://dx.doi.org/10.1016/S1074-7613(03)00326-1
, 2003, 'The anti-tumor potential of zoledronic acid', Breast, 12, http://dx.doi.org/10.1016/S0960-9776(03)80161-3
, 2002, 'Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells', Cancer Research, 62, pp. 1619 - 1623
, 2002, 'Production of osteoprotegerin by prostate cancer cells suppresses trial induced apoptosis', European Urology Supplements, 1, pp. 54 - 54, http://dx.doi.org/10.1016/s1569-9056(02)80203-2
, 2002, 'Serum osteoprotegerin levels are increased in hormone resistant prostate cancer patients', European Urology Supplements, 1, pp. 159 - 159, http://dx.doi.org/10.1016/s1569-9056(02)80621-2
, 2001, 'Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma', Blood, 98, pp. 3534 - 3540, http://dx.doi.org/10.1182/blood.V98.13.3534
, 2001, 'Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells', British Journal of Haematology, 114, pp. 414 - 421, http://dx.doi.org/10.1046/j.1365-2141.2001.02963.x
, 2001, 'Bisphosphonates and in vivo models of multiple myeloma [3] (multiple letters)', British Journal of Haematology, 113, pp. 841 - 842, http://dx.doi.org/10.1046/j.1365-2141.2001.02804-3.x
, 2001, 'Clinical disorders of bone resorption.', Novartis Foundation symposium, 232
, 2001, 'In vivo homing and differentiation characteristics of mature (CD45−) and immature (CD45+) 5T multiple myeloma cells', Experimental Hematology, 29, pp. 77 - 84, http://dx.doi.org/10.1016/S0301-472X(00)00625-1
, 2001, 'MDC-9 (adam-9/meltrin γ) functions as an adhesion molecule by binding the α
, 2001, 'The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel', British Journal of Cancer, 84, pp. 1126 - 1134, http://dx.doi.org/10.1054/bjoc.2001.1727
, 2001, 'Reply to salomo and gimsing', British Journal of Haematology, 113, pp. 842 - 842, http://dx.doi.org/10.1046/j.1365-2141.2001.02804-4.x
, 2001, 'The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases', European Journal of Cancer, 37, pp. S129 - S129, http://dx.doi.org/10.1016/s0959-8049(01)80965-5
, 2000, 'The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma', British Journal of Haematology, 111, pp. 283 - 286, http://dx.doi.org/10.1046/j.1365-2141.2000.02310.x
, 2000, 'Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts', British Journal of Haematology, 108, pp. 383 - 390, http://dx.doi.org/10.1046/j.1365-2141.2000.01845.x
, 2000, 'Human myeloma cells promote the recruitment of osteoblast precursors: Mediation by interleukin-6 and soluble interleukin-6 receptor', Journal of Bone and Mineral Research, 15, pp. 1935 - 1943, http://dx.doi.org/10.1359/jbmr.2000.15.10.1935
, 1999, 'Bisphosphonates in multiple myeloma', Pathologie Biologie, 47, pp. 178 - 181
, 1999, 'Expression of interleukin-1β and tumour necrosis factor-α in plasma cells from patients with multiple myeloma', British Journal of Haematology, 104, pp. 350 - 357, http://dx.doi.org/10.1046/j.1365-2141.1999.01193.x
, 1999, 'Interleukin-6 Receptor (IL-6R) Shedding: A Role for Members of the ADAM Family', Biochemical Society Transactions, 27, pp. A23 - A23, http://dx.doi.org/10.1042/bst027a023a
, 1998, 'Bone disease in multiple myeloma', British Journal of Haematology, 103, pp. 902 - 910, http://dx.doi.org/10.1046/j.1365-2141.1998.01082.x
, 1998, 'The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway', Cancer Research, 58, pp. 5294 - 5297
, 1998, 'Human myeloma cells shed the interleukin-6 receptor: Inhibition by tissue inhibitor of metalloproteinase-3 and a hydroxamate-based metalloproteinase inhibitor', British Journal of Haematology, 101, pp. 694 - 702, http://dx.doi.org/10.1046/j.1365-2141.1998.00754.x
, 1998, 'Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance', British Journal of Haematology, 101, pp. 287 - 295, http://dx.doi.org/10.1046/j.1365-2141.1998.00687.x
, 1998, 'Anti-tumour activity of bisphosphonates in human myeloma cells', Leukemia and Lymphoma, 32, pp. 129 - 138, http://dx.doi.org/10.3109/10428199809059253